Lexaria Bioscience Corp. (NASDAQ:LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms, provides this update on a material transfer agreement (“MTA”) originally entered into on August 30, 2024 with a pharmaceutical company (“Pharmaco”) to evaluate Lexaria’s DehydraTech.™ Technology in Pre-Clinical Settings.
original agreement To accommodate the time required for Pharmaco’s receipt and review of Lexaria’s 2026 research and development (“R&D”) results related to GLP-1, this has been successfully extended to December 31, 2026. This allows both parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and consider additional strategic planning discussions with Pharmaco’s human clinical and business development teams.
Over the past 12 months, Lexaria has taken significant steps forward in advancing its GLP-1 development program. This includes recently announced progress in each of its 2026 R&D studies: Human Study #7; Animal Study #1; And Animal Study #2. All of these studies are within the GLP-1 field and are designed with the goal of providing complete evidence to better allow additional collaboration and potential licensing of Lexaria’s technology.
Each study mentioned above is in process and fully funded from existing corporate resources. Results are expected during the third and fourth quarters of this calendar year.
About Lexaria Bioscience Corp. and DehydraTech
Dehydratech™ Lexaria’s patented drug delivery formulation and processing platform technology improves the way a variety of drugs enter the bloodstream, always via oral delivery. Dehydratec has repeatedly demonstrated the ability to increase bioabsorption, reduce side effects, and more effectively deliver certain drugs across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a strong intellectual property portfolio with 65 granted patents worldwide and additional patents pending. For more information, please visit www.lexariabioscience.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements. Such terms are defined under applicable securities laws. These statements can be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “could,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company regarding the intended use of the proceeds from the Offering and the Company’s ability to conduct research initiatives, obtain regulatory approvals or grants, or experience positive impacts or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based on current information and involve numerous risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions or expectations set forth in these forward-looking statements. Thus, you should not place undue reliance on these forward-looking statements. Factors that could cause actual results to differ materially from those anticipated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, management and maintenance of development, impact of adverse publicity, litigation, competition, scientific discovery, patent application and approval process, potential adverse effects arising from the testing or use of products utilizing DehydraTech technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delay or cancellation of planned R&D, Are not limited to. due to the pandemic or other reasons, and other factors that may be identified from time to time in the Company’s public announcements and periodic filings with the U.S. Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the completeness, accuracy, or timeliness of the information on third-party websites. There is no assurance that any of Lexaria’s anticipated uses, benefits or advantages for its patented and patent-pending technology will actually be realized in any manner or in any part. Any statements made here have not been evaluated by the Food and Drug Administration (FDA). Lexaria products are not intended to diagnose, treat, cure, or prevent any disease. Any forward-looking statement included in this release speaks only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein or links to third-party websites, whether as a result of new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Investor Contact:
George Jurasik – Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, extension 202
Click here to join Lexaria Bioscience (NASDAQ:LESX) to receive the investor presentation
